{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["CALR", "JAK2V617F", "MPL", "coexistence", "gene mutation", "myeloproliferative neoplasms"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36744404", "DateCompleted": {"Year": "2023", "Month": "02", "Day": "07"}, "DateRevised": {"Year": "2023", "Month": "06", "Day": "27"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["15330338231154092", "10.1177/15330338231154092"], "Journal": {"ISSN": "1533-0338", "JournalIssue": {"Volume": "22", "PubDate": {"Year": "2023", "Season": "Jan-Dec"}}, "Title": "Technology in cancer research & treatment", "ISOAbbreviation": "Technol Cancer Res Treat"}, "ArticleTitle": "Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in <i>JAK2V617F</i>, <i>CALR,</i> and <i>MPL</i>.", "Pagination": {"StartPage": "15330338231154092", "MedlinePgn": "15330338231154092"}, "Abstract": {"AbstractText": ["Simultaneous mutations in Janus kinase 2 (<i>JAK2)</i>, calreticulin<i>,</i> and myeloproliferative leukemia <i>(MPL)</i> genes are generally not considered for characterizing Philadelphia-negative myeloproliferative neoplasms (MPNs), leading to misdiagnosis. Sanger sequencing and quantitative polymerase chain reaction were used to detect gene mutations in patients with MPN. We retrospectively screened the data of patients with double mutations in our center and from the PubMed database. Two patients tested positive for both <i>JAK2V617F</i> and <i>CALR</i> mutations (2/352 0.57%) in our center, while data of 35 patients from the PubMed database, including 26 patients with essential thrombocythemia (ET), 6 with primary myelofibrosis (PMF), 2 with unexplained thrombosis, and 1 with polycythemia vera were screened for double mutations. Among these mutations, co-mutation of <i>JAKV617F-CALR</i> constituted the majority (80.0%), when compared with <i>JAKV617F-MPL</i> (17.1%) and <i>CALR-MPL</i> (2.9%) mutations. Moreover, patients with concurrent mutational myeloproliferative neoplasm (MPN) were relatively older (<i>P</i>\u2009\u2009=\u2009\u2009.010) with significantly higher platelet counts than their counterparts with single gene mutations (<i>P</i>\u2009<\u2009.001). The occurrence of palpable splenomegaly (<i>P</i>\u2009<\u2009.001) and leukocyte count (<i>P</i>\u2009\u2009=\u2009\u2009.041) were also significantly different between patients with single and simultaneous gene mutations. These 4 risk factors also showed significant test effectiveness in the ET and PMF cohorts (<i>P</i>\u2009<\u2009.05). In terms of clinical characteristics of patients with ET, those with <i>JAK2V617F</i>-<i>CALR</i> mutation had higher but normal hemoglobin levels (<i>P</i>\u2009\u2009=\u2009\u2009.0151) than those carrying <i>JAK2V617F</i>-<i>MPL</i> mutation. From a clinical perspective, patients with multiple mutational MPN are different from those with single gene mutations. The poor treatment response by patients in our center and unfavorable indicators for patients with co-mutations in published literature indicate that customized treatment may be the best choice for patients with MPN carrying co-mutations."]}, "AuthorList": [{"Identifier": ["0000-0003-0572-0851"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guizhou Provincial Institute of Hematological Malignancies, Guiyang, China."}], "LastName": "Wang", "ForeName": "Yan", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Laboratory Medicine, 56663Guizhou Provincial People's Hospital, Guiyang, China."}], "LastName": "Ran", "ForeName": "Fei", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Jiangxi Province Key Laboratory of Laboratory Medicine, Department of Clinical Laboratory, 196534The Second Affiliated Hospital of Nanchang University, Nanchang, China."}], "LastName": "Lin", "ForeName": "Jin", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Jiangxi Province Key Laboratory of Laboratory Medicine, Department of Clinical Laboratory, 196534The Second Affiliated Hospital of Nanchang University, Nanchang, China."}], "LastName": "Zhang", "ForeName": "Jing", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guizhou Provincial Institute of Hematological Malignancies, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}], "LastName": "Ma", "ForeName": "Dan", "Initials": "D"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Technol Cancer Res Treat", "NlmUniqueID": "101140941", "ISSNLinking": "1533-0338"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Calreticulin"}, {"RegistryNumber": "143641-95-6", "NameOfSubstance": "MPL protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, Thrombopoietin"}], "CommentsCorrectionsList": [{"RefSource": "Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231179561. doi: 10.1177/15330338231179561", "PMID": "37312522"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Retrospective Studies"}, {"QualifierName": ["genetics"], "DescriptorName": "Calreticulin"}, {"QualifierName": ["diagnosis", "genetics"], "DescriptorName": "Myeloproliferative Disorders"}, {"QualifierName": ["genetics"], "DescriptorName": "Polycythemia Vera"}, {"QualifierName": ["diagnosis", "genetics"], "DescriptorName": "Thrombocythemia, Essential"}, {"QualifierName": [], "DescriptorName": "Leukemia"}, {"QualifierName": [], "DescriptorName": "Mutation"}, {"QualifierName": ["genetics"], "DescriptorName": "Receptors, Thrombopoietin"}], "CoiStatement": "The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599-1613. doi:10.1002/ajh.26008", "ArticleIdList": ["10.1002/ajh.26008", "32974939"]}, {"Citation": "Maddali M, Kulkarni UP, Ravindra N, et al. JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis. Ann Hematol. 2020;99(5):983-989. doi:10.1007/s00277-020-04004-7", "ArticleIdList": ["10.1007/s00277-020-04004-7", "PMC7611239", "32277273"]}, {"Citation": "Perner F, Perner C, Ernst T, et al. Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells. 2019;8(8):854. doi:10.3390/cells8080854", "ArticleIdList": ["10.3390/cells8080854", "PMC6721738", "31398915"]}, {"Citation": "Araki M, Komatsu N. The role of calreticulin mutations in myeloproliferative neoplasms. Int J Hematol. 2020;111(2):200-205. doi:10.1007/s12185-019-02800-0", "ArticleIdList": ["10.1007/s12185-019-02800-0", "31848992"]}, {"Citation": "Zulkeflee RH, Zulkafli Z, Johan MF, et al. Clinical and laboratory features of JAK2 V617F, CALR, and MPL mutations in Malaysian patients with classical myeloproliferative neoplasm (MPN). Int J Environ Res Public Health. 2021;18(14):7582. doi:10.3390/ijerph18147582", "ArticleIdList": ["10.3390/ijerph18147582", "PMC8307561", "34300032"]}, {"Citation": "Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376(22):2168-2181. doi:10.1056/NEJMra1406186", "ArticleIdList": ["10.1056/NEJMra1406186", "28564565"]}, {"Citation": "Grabek J, Straube J, Bywater M, et al. MPN: the molecular drivers of disease initiation, progression and transformation and their effect on treatment. Cells. 2020;9(8):1901. doi:10.3390/cells9081901", "ArticleIdList": ["10.3390/cells9081901", "PMC7465511", "32823933"]}, {"Citation": "Imai M, Araki M, Komatsu N. Somatic mutations of calreticulin in myeloproliferative neoplasms. Int J Hematol. 2017;105(6):743-747. doi:10.1007/s12185-017-2246-9", "ArticleIdList": ["10.1007/s12185-017-2246-9", "28470469"]}, {"Citation": "Martin-Cabrera P, Haferlach C, Kern W, et al. BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance. Br J Haematol. 2017;176(1):135-139. doi:10.1111/bjh.13932", "ArticleIdList": ["10.1111/bjh.13932", "26847954"]}, {"Citation": "Ahmed RZ, Rashid M, Ahmed N, et al. Coexisting JAK2V617F and CALR exon 9 mutations in myeloproliferative neoplasms - do they designate a new subtype? Asian Pac J Cancer Prev. 2016;17(3):923-926. doi:10.7314/apjcp.2016.17.3.923", "ArticleIdList": ["10.7314/apjcp.2016.17.3.923", "27039813"]}, {"Citation": "Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. doi:10.1182/blood-2016-03-643544", "ArticleIdList": ["10.1182/blood-2016-03-643544", "27069254"]}, {"Citation": "Kim SY, Im K, Park SN, et al. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Am J Clin Pathol. 2015;143(5):635-644. doi:10.1309/ajcpuaac16liwzmm", "ArticleIdList": ["10.1309/ajcpuaac16liwzmm", "25873496"]}, {"Citation": "Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. doi:10.1038/s41408-018-0054-y", "ArticleIdList": ["10.1038/s41408-018-0054-y", "PMC5807384", "29426921"]}, {"Citation": "Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220-2228. doi:10.1182/blood-2013-11-537167", "ArticleIdList": ["10.1182/blood-2013-11-537167", "24478400"]}, {"Citation": "Fu R, Xuan M, Zhou Y, et al. Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia. 2014;28(9):1912-1914. doi:10.1038/leu.2014.138", "ArticleIdList": ["10.1038/leu.2014.138", "24732593"]}, {"Citation": "McGaffin G, Harper K, Stirling D, et al. JAK2 V617f and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Haematol. 2014;167(2):276-278. doi:10.1111/bjh.12969", "ArticleIdList": ["10.1111/bjh.12969", "24935260"]}, {"Citation": "Xu N, Ding L, Yin C, et al. A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients. Ann Hematol. 2015;94(5):865-867. doi:10.1007/s00277-014-2248-0", "ArticleIdList": ["10.1007/s00277-014-2248-0", "25366168"]}, {"Citation": "Ha J, Kim Y. Calreticulin exon 9 mutations in myeloproliferative neoplasms. Ann Lab Med. 2015;35(1):22-27. doi:10.3343/alm.2015.35.1.22", "ArticleIdList": ["10.3343/alm.2015.35.1.22", "PMC4272961", "25553276"]}, {"Citation": "Shirane S, Araki M, Morishita S, et al. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica. 2015;100(2):e46-e48. doi:10.3324/haematol.2014.115113", "ArticleIdList": ["10.3324/haematol.2014.115113", "PMC4803122", "25398833"]}, {"Citation": "Lim KH, Chang YC, Gon-Shen Chen C, et al. Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis. Blood Cancer J. 2015;5(3):e295. doi:10.1038/bcj.2015.21", "ArticleIdList": ["10.1038/bcj.2015.21", "PMC4382662", "25794131"]}, {"Citation": "Al Assaf C, Van Obbergh F, Billiet J, et al. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica. 2015;100(7):893-897. doi:10.3324/haematol.2014.118299", "ArticleIdList": ["10.3324/haematol.2014.118299", "PMC4486223", "25934766"]}, {"Citation": "Lin Y, Liu E, Sun Q, et al. The prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1-negative myeloproliferative neoplasms. Am J Clin Pathol. 2015;144(1):165-171. doi:10.1309/ajcpalp51xdixddv", "ArticleIdList": ["10.1309/ajcpalp51xdixddv", "26071474"]}, {"Citation": "Rashid M, Ahmed RZ, Ahmed S, et al. Coexisting JAK2V617F and CALR exon 9 mutation in essential thrombocythemia. Indian J Hematol Blood Transfus. 2016;32(Suppl 1):112-116. doi:10.1007/s12288-016-0658-y", "ArticleIdList": ["10.1007/s12288-016-0658-y", "PMC4925557", "27408370"]}, {"Citation": "Haunstrup LM, Ebbesen LH, Hansen M, et al. Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation. Exp Hematol. 2018;68:62-65. doi:10.1016/j.exphem.2018.09.007", "ArticleIdList": ["10.1016/j.exphem.2018.09.007", "30292681"]}, {"Citation": "Kang MG, Choi HW, Lee JH, et al. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget. 2016;7(35):57036-57049. doi:10.18632/oncotarget.10958", "ArticleIdList": ["10.18632/oncotarget.10958", "PMC5302971", "27486987"]}, {"Citation": "Usseglio F, Beaufils N, Calleja A, et al. Detection of CALR and MPL mutations in low allelic burden JAK2 V617F essential thrombocythemia. J Mol Diagn. 2017;19(1):92-98. doi:10.1016/j.jmoldx.2016.08.006", "ArticleIdList": ["10.1016/j.jmoldx.2016.08.006", "27855276"]}, {"Citation": "De Roeck L, Michaux L, Debackere K, et al. Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. Hematology. 2018;23(10):785-792. doi:10.1080/10245332.2018.1498182", "ArticleIdList": ["10.1080/10245332.2018.1498182", "29993347"]}, {"Citation": "Yang HS. Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations. Cancer Biomark. 2016;17(4):383-389. doi:10.3233/cbm-160652", "ArticleIdList": ["10.3233/cbm-160652", "27662324"]}, {"Citation": "Partouche N, Conejero C, Barathon Q, et al. Emergence of MPLW515 mutation in a patient with CALR deletion: evidence of secondary acquisition of MPL mutation in the CALR clone. Hematol Oncol. 2018;36(1):336-339. doi:10.1002/hon.2431", "ArticleIdList": ["10.1002/hon.2431", "28556926"]}, {"Citation": "G\u00e1ng\u00f3 A, M\u00f3zes R, Boha Z, et al. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. Leuk Res. 2018;65:42-48. doi:10.1016/j.leukres.2017.12.005", "ArticleIdList": ["10.1016/j.leukres.2017.12.005", "29306106"]}, {"Citation": "Jang MA, Seo MY, Choi KJ, et al. A rare case of essential thrombocythemia with coexisting JAK2 and MPL driver mutations. J Korean Med Sci. 2020;35(23):e168. doi:10.3346/jkms.2020.35.e168", "ArticleIdList": ["10.3346/jkms.2020.35.e168", "PMC7295601", "32537949"]}, {"Citation": "Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507-2513; quiz 2615. doi:10.1182/blood-2014-05-579136", "ArticleIdList": ["10.1182/blood-2014-05-579136", "PMC4199952", "25037629"]}, {"Citation": "Zamora L, Xicoy B, Cabez\u00f3n M, et al. Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis. Leuk Lymphoma. 2015;56(10):2973-2974. doi:10.3109/10428194.2015.1015124", "ArticleIdList": ["10.3109/10428194.2015.1015124", "25686645"]}, {"Citation": "Murugesan G, Guenther-Johnson J, Mularo F, et al. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR. Int J Lab Hematol. 2016;38(3):284-297. doi:10.1111/ijlh.12484", "ArticleIdList": ["10.1111/ijlh.12484", "27018326"]}, {"Citation": "Mansier O, Luque Paz D, Ianotto JC, et al. Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol. 2018;93(4):E84-e86. doi:10.1002/ajh.25014", "ArticleIdList": ["10.1002/ajh.25014", "29266414"]}, {"Citation": "Schulze S, Stengel R, Jaekel N, et al. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515\u2009L-positive myelofibrosis. Genes Chromosomes Cancer. 2019;58(11):747-755. doi:10.1002/gcc.22781", "ArticleIdList": ["10.1002/gcc.22781", "31135094"]}, {"Citation": "Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94(4):599-610. doi:10.1016/j.mayocp.2018.08.022", "ArticleIdList": ["10.1016/j.mayocp.2018.08.022", "30824279"]}, {"Citation": "Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol. 2012;87(5):552-554. doi:10.1002/ajh.23160", "ArticleIdList": ["10.1002/ajh.23160", "22473827"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "2", "Day": "6", "Hour": "4", "Minute": "13"}, {"Year": "2023", "Month": "2", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "6"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36744404", "PMC9905029", "10.1177/15330338231154092"]}}], "PubmedBookArticle": []}